What does this research mean for the field?

Emicizumab prophylaxis significantly reduces the rate and severity of bleeding events in people with hemophilia A across different real-world clinical settings. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate real-world characteristics, adherence patterns, and bleeding outcomes of patients with hemophilia A receiving emicizumab from the perspective of treating physicians.

September 5, 2026Haemophilia

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

View Full Paper

Ask AI

Bookmark

To evaluate real-world characteristics, adherence patterns, and bleeding outcomes of patients with hemophilia A receiving emicizumab from the perspective of treating physicians.
Cross-sectional, retrospective survey from the Adelphi Real World Hemophilia Disease Specific Programme involving 54 US hematology and hematology-oncology specialists between July 2023 and April 2024.
Sample included male patients with hemophilia A (with or without inhibitors) and baseline factor VIII levels <5% not enrolled in clinical trials (N=293, with n=77 receiving emicizumab and n=49 with pre- and post-initiation data; median follow-up: 12.0 months).
Patients with zero treated bleeds increased from 42.9% in the 12 months pre-initiation to 76.9% during the post-emicizumab observation period.
Treated bleeding events significantly decreased from a mean (SD) of 1.3 (1.9) pre-initiation to 0.4 (1.1) post-initiation (p = 0.0001).
High treatment adherence was observed, with patients taking a mean (SD) of 90.7% (14.6%) of doses on time and 64.0% taking >80% of the prescribed dose across federally funded and non-federally funded centers.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study shows reduced bleeding events with emicizumab in males with hemophilia A, indicating real-world efficacy across diverse clinical settings.

Cite This Study

Recht et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4216b95aff0620eb977 https://doi.org/10.1111/hae.70394

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study shows reduced bleeding events with emicizumab in males with hemophilia A, indicating real-world efficacy across diverse clinical settings.

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

Key Points

Discussion

Implication

Cite This Study

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading